SOX11 and nasopharyngeal carcinoma: SOX11 was reported to be highly expressed in breast cancer [17], mantle cell lymphoma [18], epithelial ovarian cancer [19] and hepatocellular carcinoma [20], while it was expressed at low levels in nasopharyngeal carcinoma [21], prostate cancer [22], gastric cancer (GC) [23] and bladder cancer [24].